Roscovitine (Seliciclib, CYC202): Selective CDK2 Inhibitor for Cancer Research

Executive Summary: Roscovitine (Seliciclib, CYC202) is a potent small-molecule inhibitor that targets cyclin-dependent kinases (CDKs) with high selectivity and nanomolar efficacy, specifically CDK2/cyclin E (IC₅₀ = 0.1 μM) and other CDK isoforms (IC₅₀ < 1 μM) in biochemical assays (Moret et al., 2019). It induces cell cycle arrest in late prophase and blocks the prophase/metaphase transition in multiple animal models. In vivo, Roscovitine substantially suppresses tumor growth in murine xenograft models, validating its translational relevance. The compound is recommended for research on CDK signaling, cell cycle control, and apoptosis. Roscovitine’s physical-chemical properties—water insolubility, DMSO and ethanol solubility, and stability at -20°C—require protocol-specific handling (product page).

Biological Rationale

Cyclin-dependent kinases (CDKs) regulate cell cycle progression and are frequently deregulated in human cancers (Moret et al., 2019). CDK2, in complex with cyclin E, governs the G1/S phase transition. Dysregulation of CDK2 activity is implicated in uncontrolled proliferation and tumorigenesis. Selective inhibition of CDK2 and related kinases allows precise dissection of cell cycle checkpoints and identification of vulnerabilities in cancer cells. Roscovitine (Seliciclib, CYC202) is designed to selectively target CDK2 and several related kinases with minimal off-target effects, supporting its use in both mechanistic research and preclinical oncology (product page).

Mechanism of Action of Roscovitine (Seliciclib, CYC202)

Roscovitine is an ATP-competitive inhibitor of CDKs. It binds the ATP-binding site of CDK2/cyclin E with an IC₅₀ of 0.1 μM, CDK7/cyclin H (IC₅₀ = 0.49 μM), CDK5/p35 (IC₅₀ = 0.16 μM), and CDC2/cyclin B (IC₅₀ = 0.65 μM). At higher concentrations, it inhibits ERK1 (IC₅₀ = 34 μM) and ERK2 (IC₅₀ = 14 μM), but these values are significantly above its active range for CDKs. Roscovitine’s selectivity has been validated across multiple kinase profiling panels (Moret et al., 2019). Upon CDK inhibition, Roscovitine arrests cells in late prophase, preventing the prophase/metaphase transition. This phenotype has been demonstrated in Xenopus oocytes, starfish oocytes, and sea urchin embryos, indicating a conserved mode of action in eukaryotic cells.

Evidence & Benchmarks

• Roscovitine inhibits CDK2/cyclin E activity with IC₅₀ = 0.1 μM in biochemical assays (Moret et al., 2019).
• CDK7/cyclin H is inhibited with IC₅₀ = 0.49 μM; CDK5/p35 with IC₅₀ = 0.16 μM; and CDC2/cyclin B with IC₅₀ = 0.65 μM (Moret et al., 2019).
• Inhibition of ERK1 (IC₅₀ = 34 μM) and ERK2 (IC₅₀ = 14 μM) occurs at much higher concentrations, indicating substantial kinase selectivity (Moret et al., 2019).
• In vivo, Roscovitine treatment (dose and schedule as specified in primary literature) reduced tumor volume in athymic nude mice bearing A4573 tumors compared to vehicle controls (Moret et al., 2019).
• Roscovitine is insoluble in water but soluble in DMSO (≥17.72 mg/mL) and ethanol (≥53.5 mg/mL) at room temperature; solutions are stable at -20°C for short-term use (product page).

Applications, Limits & Misconceptions

Roscovitine is primarily used for research into cell cycle regulation, apoptosis, and cancer biology. Its selectivity for CDKs makes it a valuable chemical probe for dissecting cyclin-dependent kinase signaling pathways. Roscovitine has empowered translational research, as discussed in Harnessing Selective CDK2 Inhibition for a New Era in Translational Oncology, by providing mechanistic clarity and robust preclinical validation. This article extends those insights by detailing the quantitative benchmarks and practical workflows for experimental success.

Additional perspectives on experimental design and troubleshooting can be found in Roscovitine: A Selective CDK2 Inhibitor for Precision Cancer Research, but the present article clarifies product-specific handling and benchmarking for rigorous reproducibility. For cheminformatics-driven applications and library design, see Roscovitine (Seliciclib, CYC202): Cheminformatics-Driven Cancer Biology; we update these findings with the latest IC₅₀ and selectivity data.

Common Pitfalls or Misconceptions

• Roscovitine is not effective at inhibiting kinases outside the CDK family at concentrations below 10 μM; off-target effects are minimal at standard working concentrations.
• It is not water-soluble; attempts to dissolve in aqueous buffers without co-solvent will fail.
• The compound is not suitable for long-term solution storage; degradation can occur above -20°C or after repeated freeze-thaw cycles.
• Roscovitine does not induce cell death in all cell lines; apoptosis is context-dependent and may require combination with other agents.
• High concentrations may impact ERK1/2, but these effects are not observed in standard protocols using ≤1 μM concentrations.

Workflow Integration & Parameters

For optimal solubility, dissolve Roscovitine in DMSO to ≥17.72 mg/mL or in ethanol to ≥53.5 mg/mL. Warming and ultrasonic treatment can facilitate dissolution. Stock solutions should be aliquoted and stored at -20°C for short-term use. Thaw only once to avoid degradation. Working concentrations in cell-based assays typically range from 0.1 μM to 10 μM, depending on the sensitivity of the model system. For in vivo studies, dosing regimens should follow established protocols and be justified by pharmacokinetic and toxicity considerations. Roscovitine’s selectivity profile supports its use in both single-agent and combination studies targeting CDK-driven pathways. Integration into focused small-molecule libraries, as highlighted by cheminformatics-guided design (Moret et al., 2019), enhances target coverage and reduces off-target effects relative to legacy CDK inhibitors.

Conclusion & Outlook

Roscovitine (Seliciclib, CYC202) remains a benchmark tool for selective CDK inhibition in cancer research. Its quantitative potency, characterized selectivity, and robust in vivo efficacy support ongoing applications in cell cycle, apoptosis, and translational oncology studies. Future directions include integration into optimized chemical libraries and combination strategies for overcoming resistance. For the latest product specifications and ordering, see the Roscovitine (Seliciclib, CYC202) A1723 product page.